Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 1475

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7A
Chunk 1475
---

    Accounts payable and accrued expenses 
    $1,897,127  
    $4,620,925 

    Accrued compensation 
     —  
     645,947 

    Investor Note, net of debt discount 
     —  
     316,324 

    Loan payable, net of debt discount 
     2,054,202  
     202,279 

    Loan payable - related party, net of debt discount 
     131,868  
     750,082 

    Due to Chromocell Corporation 
     —  
     5,386 

    TOTAL CURRENT LIABILITIES 
     4,083,197  
     6,540,943 

    TOTAL LIABILITIES 
     4,083,197  
     6,540,943 

    COMMITMENTS AND CONTINGENCIES 
     -   

    STOCKHOLDERS’ DEFICIT 

    Preferred stock Series A, $0.0001 par value, 700,000 shares authorized, 0 and 600,000 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 
     —  
     60 

    Preferred stock Series C, $0.0001 par value, 5,000 shares authorized, 2,600 and 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 
     —  
     — 

    Common stock, $0.0001 par value, 200,000,000 shares authorized, 6,103,813 and 3,906,300 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 
     613  
     391 

    Additional paid in capital 
     18,760,320  
     7,074,646 

    Accumulated deficit 
     (21,474,987) 
     (13,519,649)

    TOTAL STOCKHOLDERS’ DEFICIT 
     (2,714,054) 
     (6,444,552)

    TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT 
    $1,369,